Q-omics provides the consensus-scored IL27RA profile across patient tissues and cancer cell-line models. IL27RA expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, IL27RA is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, IL27RA RNA expression shows 17,626 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where IL27RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL27RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL27RA survival associations across molecular data types. IL27RA RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL27RA RNA expression–survival associations across cancer types. High IL27RA expression shows unfavorable associations in MESO, UVM, KIRP, ACC and COAD, but favorable associations in STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for IL27RA RNA expression.
This table summarizes IL27RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL27RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL27RA shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, HNSC and KIRP. The KIRC box plot shows higher IL27RA RNA expression in tumor versus normal tissue (log2 FC = +1.236, t-test p < 0.001).
This table shows molecular features associated with IL27RA in patient tissues and cancer cell lines. In patient samples, IL27RA shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL27RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
